Michael Chapman, MD

Denver, Colorado, United States
Michael P. Chapman MD, CEO of ThromboTherapeutics Inc., is a physician/scientist at the University of Colorado, working and conducting research in interventional radiology, traumatic injury, critical care, coagulation management, and kidney disease. Inventor of the DIFF™ assay and Rapid Plasma System and co-inventor of the tPA-Challenge™ assay, he also has more than 30 publications and six patents in the field of coagulation management, as well as a background in MEMS/NEMS engineering.
Speaking In
9:00 AM - 9:15 AM
Wednesday, October 23
ThromboTherapeutics Inc. (TTI) is a medical therapeutics and diagnostics startup, founded in 2017…